A study by Sengupta et al. (2017), is one of the few, if not the only one looking at tau oligomers levels in CSF human samples of moderate to severe AD, mild AD, and control patients (Dorey et al., 2015; Sengupta et al., 2017). Here, MAPT is linked to Alzheimer disease.